These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35611653)

  • 1. Clinical Outcomes of Treated and Untreated C. difficile PCR-Positive/Toxin-Negative Adult Hospitalized Patients: a Quasi-Experimental Noninferiority Study.
    Hogan CA; Hitchcock MM; Frost S; Kapphahn K; Holubar M; Tompkins LS; Banaei N
    J Clin Microbiol; 2022 Jun; 60(6):e0218721. PubMed ID: 35611653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Reporting of Clostridioides difficile PCR and Predicted Toxin Result Based on PCR Cycle Threshold Reduces Treatment of Toxin-Negative Patients without Increases in Adverse Outcomes.
    Hitchcock MM; Holubar M; Hogan CA; Tompkins LS; Banaei N
    J Clin Microbiol; 2019 Nov; 57(11):. PubMed ID: 31511334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.
    Polage CR; Gyorke CE; Kennedy MA; Leslie JL; Chin DL; Wang S; Nguyen HH; Huang B; Tang YW; Lee LW; Kim K; Taylor S; Romano PS; Panacek EA; Goodell PB; Solnick JV; Cohen SH
    JAMA Intern Med; 2015 Nov; 175(11):1792-801. PubMed ID: 26348734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Impact of Clostridium difficile PCR Cycle Threshold-Predicted Toxin Reporting in Pediatric Patients.
    Schwenk HT; Bio LL; Kruger JF; Banaei N
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):44-50. PubMed ID: 30476169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
    Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
    Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and outcomes of
    Crone AS; Wright LM; Cheknis A; Johnson S; Pacheco SM; Skinner AM
    Infect Control Hosp Epidemiol; 2024 Jan; 45(1):57-62. PubMed ID: 37462099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease.
    Gupta A; Wash C; Wu Y; Sorrentino D; Nguyen VQ
    Dig Dis Sci; 2021 Feb; 66(2):547-553. PubMed ID: 32207033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients.
    Miller R; Morillas JA; Brizendine KD; Fraser TG
    J Clin Microbiol; 2020 Feb; 58(3):. PubMed ID: 31896665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
    Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
    Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Cycle Threshold, Toxin Concentration, and Clinical Characteristics of Clostridioides difficile Infection in Patients with Discordant Diagnostic Test Results.
    Shah MD; Balada-Llasat JM; Coe K; Reed E; Sandlund J; Pancholi P
    J Clin Microbiol; 2020 Apr; 58(5):. PubMed ID: 32051264
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of Risk Factors for Clostridium difficile Infection Based on Immunochromatography Testing and Toxigenic Culture Assay.
    Ohshima T; Osaki T; Yamamoto Y; Asai S; Miyachi H; Kamiya S
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30232129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the clinical course of Clostridium difficile infection in glutamate dehydrogenase-positive toxin-negative patients diagnosed by PCR to those with a positive toxin test.
    Origüen J; Corbella L; Orellana MÁ; Fernández-Ruiz M; López-Medrano F; San Juan R; Lizasoain M; Ruiz-Merlo T; Morales-Cartagena A; Maestro G; Parra P; Villa J; Delgado R; Aguado JM
    Clin Microbiol Infect; 2018 Apr; 24(4):414-421. PubMed ID: 28811244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates.
    Guh AY; Hatfield KM; Winston LG; Martin B; Johnston H; Brousseau G; Farley MM; Wilson L; Perlmutter R; Phipps EC; Dumyati GK; Nelson D; Hatwar T; Kainer MA; Paulick AL; Karlsson M; Gerding DN; McDonald LC
    Clin Infect Dis; 2019 Oct; 69(10):1667-1674. PubMed ID: 30615074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay.
    Pollock NR; Banz A; Chen X; Williams D; Xu H; Cuddemi CA; Cui AX; Perrotta M; Alhassan E; Riou B; Lantz A; Miller MA; Kelly CP
    Clin Infect Dis; 2019 Jan; 68(1):78-86. PubMed ID: 29788296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular-based diagnosis of Clostridium difficile infection is associated with reduced mortality.
    Avni T; Babich T; Ben-Zvi H; Atamna A; Yahav D; Shepshelovich D; Leibovici-Weissman Y; Bishara J
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1137-1142. PubMed ID: 29627950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in
    Origüen J; Orellana MÁ; Fernández-Ruiz M; Corbella L; San Juan R; Ruiz-Ruigómez M; López-Medrano F; Lizasoain M; Ruiz-Merlo T; Maestro-de la Calle G; Parra P; Villa J; Delgado R; Aguado JM
    J Clin Microbiol; 2019 Feb; 57(2):. PubMed ID: 30463889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the Association Between Diagnostic Testing Method, Polymerase Chain Reaction Ribotype, and Clinical Outcomes From Clostridioides difficile Infection: One Institution's Experience.
    Menon A; Perry DA; Motyka J; Weiner S; Standke A; Penkevich A; Keidan M; Young VB; Rao K
    Clin Infect Dis; 2021 Nov; 73(9):e2883-e2889. PubMed ID: 32930705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients.
    Erb S; Frei R; Strandén AM; Dangel M; Tschudin-Sutter S; Widmer AF
    Clin Microbiol Infect; 2015 Nov; 21(11):998.e9-998.e15. PubMed ID: 26232535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridioides difficile PCR Tcdb Cycle Threshold predicts toxin EIA positivity but not severity of infection.
    Mah R; Locher K; Steiner TS; Stefanovic A
    Anaerobe; 2023 Aug; 82():102755. PubMed ID: 37406762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.
    Kelly CP; Chen X; Williams D; Xu H; Cuddemi CA; Daugherty K; Barrett C; Miller M; Foussadier A; Lantz A; Banz A; Pollock NR
    Clin Infect Dis; 2020 Mar; 70(6):1083-1093. PubMed ID: 31211839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.